ATE370749T1 - Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie - Google Patents

Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie

Info

Publication number
ATE370749T1
ATE370749T1 AT95944270T AT95944270T ATE370749T1 AT E370749 T1 ATE370749 T1 AT E370749T1 AT 95944270 T AT95944270 T AT 95944270T AT 95944270 T AT95944270 T AT 95944270T AT E370749 T1 ATE370749 T1 AT E370749T1
Authority
AT
Austria
Prior art keywords
compositions
viscosity
gene therapy
increasing polymer
polymer pvp
Prior art date
Application number
AT95944270T
Other languages
English (en)
Inventor
Alain Rolland
Russell J Mumper
Original Assignee
Valentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc filed Critical Valentis Inc
Application granted granted Critical
Publication of ATE370749T1 publication Critical patent/ATE370749T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT95944270T 1995-01-13 1995-12-28 Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie ATE370749T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/372,213 US6040295A (en) 1995-01-13 1995-01-13 Formulated nucleic acid compositions and methods of administering the same for gene therapy

Publications (1)

Publication Number Publication Date
ATE370749T1 true ATE370749T1 (de) 2007-09-15

Family

ID=23467181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95944270T ATE370749T1 (de) 1995-01-13 1995-12-28 Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie

Country Status (8)

Country Link
US (2) US6040295A (de)
EP (1) EP0794798B1 (de)
JP (1) JPH11502507A (de)
AT (1) ATE370749T1 (de)
AU (1) AU703419B2 (de)
CA (1) CA2210132A1 (de)
DE (1) DE69535576T2 (de)
WO (1) WO1996021470A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475795B1 (en) * 1991-07-03 2002-11-05 Meditech Research, Ltd. Use of hyaluronan in gene therapy
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6627616B2 (en) * 1995-12-13 2003-09-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
DE69736692T2 (de) * 1996-07-16 2007-06-14 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
WO1998017317A2 (de) * 1996-10-23 1998-04-30 Skw Trostberg Aktiengesellschaft Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
CA2242035C (en) * 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
AU8569698A (en) 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
AU8589998A (en) 1997-07-24 1999-02-16 Valentis, Inc. Ghrh expression system and methods of use
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors
CA2323604A1 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
WO1999059638A2 (en) * 1998-05-15 1999-11-25 Chiron Corporation Compositions and methods for the delivery of nucleic acid molecules
FR2781677B1 (fr) * 1998-07-31 2000-10-20 Brothier Lab Dispositif de traitement de plaies et procede de fabrication de ce dispositif
WO2000009086A2 (en) * 1998-08-14 2000-02-24 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
AU6394399A (en) 1998-09-18 2000-04-10 Rockefeller University, The Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US7279318B1 (en) 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
AU6389000A (en) * 1999-07-28 2001-02-19 Valentis, Inc. Sonoporation of tumors
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
IT1316990B1 (it) * 2000-02-17 2003-05-26 Sigma Tau Ind Farmaceuti Metodo per aumentare l'espressione genica per geni trasfettati.
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
ATE511400T1 (de) * 2000-03-03 2011-06-15 Genetronics Inc Nukleinsäure-fomulierungen zur genverabreichung
US6875748B2 (en) * 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
CA2426582A1 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions
WO2003056007A1 (fr) * 2001-12-26 2003-07-10 Canon Kabushiki Kaisha Materiau de sonde
FR2835749B1 (fr) 2002-02-08 2006-04-14 Inst Nat Sante Rech Med Composition pharmaceutique ameliorant le transfert de gene in vivo
AU2003219805B2 (en) * 2002-02-15 2009-06-04 Eisai Inc. Electroporation methods for introducing bioactive agents into cells
WO2003106636A2 (en) * 2002-06-14 2003-12-24 Mirus Corporation Novel methods for the delivery of polynucleotides to cells
EP1545432A4 (de) * 2002-09-26 2007-03-14 Pfizer Prod Inc Verwendung von hilfsstoffen zur erhöhung der dna-aufnahme durch schweine-muskelzellen
CN1703198A (zh) * 2002-10-25 2005-11-30 辉瑞产品公司 呈混悬剂形式的芳基杂环活性物质的贮库制剂
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
US20050014714A1 (en) * 2003-06-04 2005-01-20 The Johns Hopkins University Gene delivery to organs
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US20080044472A1 (en) * 2004-01-23 2008-02-21 Garcia Antonio A Photoresponsive Hydrogels
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
WO2006086775A2 (en) * 2005-02-11 2006-08-17 Duke University Methods and compositions for reducing systemic toxicity of vectors
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
WO2006099574A2 (en) * 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
US9163257B2 (en) * 2005-06-20 2015-10-20 Cadila Healthcare Limited Expression vector and methods of producing high levels of proteins
CN102164618A (zh) * 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
US20070287741A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US8227437B2 (en) * 2006-06-22 2012-07-24 Tai June Yoo Restoration of hearing loss
US20080221013A1 (en) * 2006-09-02 2008-09-11 Julie Miwa Neurobiological compositions
EP2114153B1 (de) * 2007-02-06 2016-11-23 Tai June Yoo Behandlung und prävention neurodegenerativer erkrankungen mithilfe einer gentherapie
US8790701B2 (en) * 2008-04-28 2014-07-29 Surmodics, Inc. Poly-α(1→4)glucopyranose-based matrices with hydrazide crosslinking
EP2299953B1 (de) 2008-07-14 2017-04-12 Polypid Ltd. Arzneimittelträgerzusammensetzung mit verzögerter freisetzung
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010074540A2 (ko) * 2008-12-26 2010-07-01 주식회사 삼양사 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
IN2012DN00570A (de) 2009-07-14 2015-06-12 Polypid Ltd
EP2525778B1 (de) 2010-01-19 2018-08-01 Polypid Ltd. Nucleinsäurematrixzusammensetzungen mit verzögerter freisetzung
EP2462952A1 (de) 2010-12-10 2012-06-13 Medizinische Universität Graz Krebsgentherapie unter Verwendung von US28-codierenden Nukleinsäuren
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
US10279079B2 (en) * 2011-07-05 2019-05-07 The Research Foundation For The State University Of New York Compositions and methods for spinal disc repair and other surgical and non-surgical indications
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
EP3375457B1 (de) 2011-11-24 2020-06-24 Positec Power Tools (Suzhou) Co., Ltd Peptidsequenzentwurf und verwendung davon für peptid-vermittelte sirna-abgabe
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
CA2903248C (en) * 2013-03-01 2023-02-28 Board Of Trustees Of The University Of Arkansas Antireflective coating for glass applications and method of forming same
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
JP6961504B2 (ja) * 2018-01-26 2021-11-05 国立大学法人 岡山大学 徐放性デバイス

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489769A1 (en) * 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
EP0558697A1 (de) 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Lokale oligonukleotiden Behandlung
GB9114180D0 (en) 1991-07-01 1991-08-21 Amersham Int Plc Enhancement of polynucleotide hybridisation
BR9206593A (pt) * 1991-10-04 1995-11-28 Gs Biochem Ab Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US5817321A (en) 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
EP0695186A1 (de) * 1993-04-28 1996-02-07 Ribozyme Pharmaceuticals, Inc. Verabreichung von nukleinsäuren an das auge
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995010265A1 (en) 1993-10-15 1995-04-20 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
EP0804249A2 (de) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5686071A (en) 1995-06-06 1997-11-11 Per Immune Holdings, Inc. Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents

Also Published As

Publication number Publication date
EP0794798B1 (de) 2007-08-22
US6040295A (en) 2000-03-21
US20020103142A1 (en) 2002-08-01
DE69535576T2 (de) 2008-05-21
AU703419B2 (en) 1999-03-25
JPH11502507A (ja) 1999-03-02
WO1996021470A2 (en) 1996-07-18
US6514947B2 (en) 2003-02-04
CA2210132A1 (en) 1996-07-18
WO1996021470A3 (en) 1996-09-06
AU4611096A (en) 1996-07-31
EP0794798A2 (de) 1997-09-17
DE69535576D1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
ATE370749T1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
BR9910251A (pt) Estimulação hematopoiética
WO2001030965A3 (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
Serša et al. Electrochemotherapy: variable anti-tumor effect on different tumor models
EP0939590A4 (de) Verabreichung therapeutischer genprodukte durch intestinale zell-expression
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
WO1997042975A3 (en) Chitosan related compositions for delivery of nucleic acids into a cell
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
FI970115A0 (fi) Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt
CA2392284A1 (en) Medical device
PT932411E (pt) Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante
ATE410518T1 (de) Kompaktnukleinsäure und ihre verabreichung in zellen
DE69527049D1 (de) Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
RU94046426A (ru) Фармацевтические композиции, способы лечения лейкоза, способ повышения уровней стволовых клеток, антагонист с - kit - лиганда, антисмысловая нуклеиновая кислота, способ лечения меланомы, способ усиления трансфекции, способ переноса гена, способ увеличения уровней периферической крови, способ повышения уровней тромбоцитов, способы модификации биологической функции, способ лечения анемии, способ улучшения приживления костного мозга, способ ускорения восстановления костного мозга, способ лечения лейкопении
ATE215099T1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
ATE231388T1 (de) Lang wirksames mittel zur rektalen verabreichung
Prota et al. Phaeomelanic pigments from a human melanoma
PH27214A (en) N-2,3-butadienyl tri and tetraaminoalkane derivatives
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
DE69028320D1 (de) Illudin-analoge, verwendet als antitumormittel
ATE243531T1 (de) Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie
IT1271342B (it) Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le contengono

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee